The evaluation efficacy of Desmopressin in improvement coagulation status of patients with combined factor V and VIII deficiency.

The evaluation efficacy of Desmopressin (1-deamino-8-D arginine Vasopressin) in increasing coagulation factor V and VIII in patients with combined factor V and VIII deficiency.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015020120894N1

Enrollment

Registered

2015-04-25

Start date

2009-11-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Combined factor V and VIII deficiency. Hereditary deficiency of other clotting factors

Interventions

Injection of 0.4 micrograms per kilogram of body weight (mcg/kg) of Desmopressin by 50 ml of 0.9% sodium chloride via intra-venous route over period of 20 minutes..

Treatment - Drugs

Injection of 0.4 micrograms per kilogram of body weight (mcg/kg) of Desmopressin by 50 ml of 0.9% sodium chloride via intra-venous route over period of 20 minutes.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Confirmed affection with combined factor V and VIII deficiency using an identification card of hemophilia center or coagulation laboratory sheet showing diagnosis of combined factor V and VIII deficiency; Having more than 18 years old officially; Agreement to accompanying in research and signing informed consort form after auscultation details and process of blood sampling and blood volume; Not infusion of factor VIII during last 48 hours; Not infusion of fresh frozen plasma or cryopercipitate during last 48 hours; 6-Not having active bleeding in time of accompanying in research. Exclusion criteria: 1-Affection to other similar coagulation disorders, inter alia, combined factor VIII & IX deficiency. 2-Havingless than 18 years old officially. 3-Not agreement to accompanying in research and signing informed consort form after auscultation details and process of blood sampling and blood volume. 4-Infusion of factor VIII during last 48 hours. 5-Infusion of fresh frozen plasma during last 48 hours. 6-Having active bleeding in time of accompanying in research.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Plasma level of coagulation factor V. Timepoint: One hour after termination of DDAVP injection. Method of measurement: According to standard one-stage APTT method.;Plasma level of coagulation factor VIII. Timepoint: One hour after termination of DDAVP injection. Method of measurement: According to standard one-stage APTT method.	—

Secondary

Measure	Time frame
?Flushing. Timepoint: One hour after injection of Desmopressin. Method of measurement: Appearance of flushing in face and felling of warmness by the patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHassan Mansouritorghabeh

Mashhad University of Medical Sciences

mansouritorghabeh@mums.ac.ir+98 51 3801 2830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026